# Mass Balance Study of [14C]Chiauranib

> **NCT05371899** · NA · COMPLETED · sponsor: **Chipscreen Biosciences, Ltd.** · enrollment: 6 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Chiauranib

## Key facts

- **NCT ID:** NCT05371899
- **Lead sponsor:** Chipscreen Biosciences, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-20
- **Primary completion:** 2024-03-18
- **Final completion:** 2024-03-18
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2024-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05371899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05371899, "Mass Balance Study of [14C]Chiauranib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05371899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*